In real-world data, Morita et al. reported that steroid use before treatment, malignant pleural effusion, and baseline CRP levels > 1.0 mg/dL decreased the response to first-line pembrolizumab in NSCLC patients with PD-L1 expression ≥ 50%16. The gene discussed is CRP; the disease is non-small cell lung carcinoma.